ArticleJournal of clinical microbiology2010
Comparison of the Vitek 2 antifungal susceptibility system with the clinical and laboratory standards institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the Sensititre YeastOne and Etest techniques for in vitro detection of antifungal resistance in yeast isolates.
Article in Journal of clinical microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Evolving Epidemiology and Emerging Antifungal Resistance in Vulvovaginal Candidosis: Evidence from a Five-Year Survey.Pathogens (Basel, Switzerland) · 2026Article
- Synergistic effect of lactoferrin combined with fluconazole to overcome antifungal resistance in Candida species.Annals of clinical microbiology and antimicrobials · 2025Article
- Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods.JAC-antimicrobial resistance · 2025Article
- Candidal speciation and carriage in oral cavity of HIV-positive children/adults and healthy individuals in the South Canara district of India: a comparative study.BMC research notes · 2025Article
- Comparative evaluation of sensititre YeastOne and VITEK2 antifungal susceptibility tests with CLSI broth microdilution method of clinicalMicrobiology spectrum · 2025Article
- Comparative evaluation of antifungal susceptibility testing methods of invasive Candida species and detection of FKS genes mutations in caspofungin intermediate and resistant isolates.BMC infectious diseases · 2025Article
- The Antimicrobial Resistance ofJournal of fungi (Basel, Switzerland) · 2025Article
- Characterization of the antagonistic secondary metabolites ofFrontiers in microbiology · 2025Article
- An AIE-active probe acts as novel tool for rapid and accurate quantitative antifungal susceptibility assessment.Frontiers in microbiology · 2025Article
- Associations between Genomic Variants and Antifungal Susceptibilities in the Archived GlobalJournal of fungi (Basel, Switzerland) · 2024Article
- The antibacterial activity and mechanism of a novel peptide MR-22 against multidrug-resistantFrontiers in cellular and infection microbiology · 2024Article
- High-Throughput Monitoring of Pathogenic Fungal Growth Using Whole Slide Imaging for Rapid Antifungal Susceptibility Assessment.Analytical letters · 2024Article
- Multicentre Surveillance ofMicroorganisms · 2023Article
- A pseudo-outbreak ofFrontiers in cellular and infection microbiology · 2023Article
- Advanced approach for antifungal susceptibility and characterization of resistance properties in clinical and environmental isolates ofInfectious medicine · 2022Article
- Commercial Methods for Antifungal Susceptibility Testing of Yeasts: Strengths and Limitations as Predictors of Resistance.Journal of fungi (Basel, Switzerland) · 2022Review
- Increasing Incidence and Shifting Epidemiology of Candidemia in Greece: Results from the First Nationwide 10-Year Survey.Journal of fungi (Basel, Switzerland) · 2022Article
- Article
- Antifungal Susceptibility Testing: A Primer for Clinicians.Open forum infectious diseases · 2021Review
- Emergence of resistantJAC-antimicrobial resistance · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The commercial technique Vitek 2 system for antifungal susceptibility testing of yeast species was evaluated. A collection of 154 clinical yeast isolates, including amphotericin B- and azole-resistant organisms, was tested. Results were compared with those obtained by the reference procedures of both the CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Two other commercial techniques approved for clinical use, the Etest and the Sensititre YeastOne, were included in the comparative exercise as well. The average essential agreement (EA) between the Vitek 2 system and the reference procedures was >95%, comparable with the average EAs observed between the reference procedures and the Sensititre YeastOne and Etest. The EA values were >97% for Candida spp. and stood at 92% for Cryptococcus neoformans. Intraclass correlation coefficients (ICC) between the commercial techniques and the reference procedures were statistically significant (P<0.01). Percentages of very major errors were 2.6% between Vitek 2 and the EUCAST technique and 1.6% between Vitek 2 and the CLSI technique. The Vitek 2 MIC results were available after 14 to 18 h of incubation for all Candida spp. (average time to reading, 15.5 h). The Vitek 2 system was shown to be a reliable technique to determine antifungal susceptibility testing of yeast species and a more rapid and easier alternative for clinical laboratories than the procedures developed by either the CLSI or EUCAST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.